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AN EVALUATION OF STATISTICAL METHODS USED TO ANALYSE PATIENT-
REPORTED OUTCOMES (PRO) DATA IN PUBLISHED METASTATIC CANCER
STUDIES
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OBJECTIVES: As metastatic cancers are generally incurable, treatment goal is to
control the cancer and relieve symptoms with minimal side effects, making pa-
tient-reported outcomes (PRO) of particular interest in addition to traditional clin-
ical outcomes. The objective of this literature review was to explore and evaluate
the PRO data analyses reported in published metastatic cancer studies.METHODS:
The literature search was conducted on Medline and Embase databases (1999-
2009). The search focused on two types of PRO analyses: the association between
PRO scores and clinical outcomes, and the assessment of treatment benefit in
terms of PROs. General keywords related to the tumour site and PROs, and key-
words specific to each type of analysis were defined. A total of 931 different ab-
stracts were reviewed by one statistician, among which 47 were finally selected for
in-depth review based on their relevance to review objectives. RESULTS: The rela-
tionship between PRO scores and clinical outcomes was mainly analysed with Cox
models, since clinical endpoint was generally survival. When analyses did not
involve survival, the association between PRO and clinical outcomes and the use of
PRO scores as endpoints were appropriately analysed with various descriptive,
non-parametric and parametric statistical methods, depending on parameters like
study objectives, design, PRO endpoints used and sample size. Only a few studies
discussed the clinical meaningfulness of results alongside statistical significance.
CONCLUSIONS: While a clear consistency was found in the statistical method for
the analysis of the link between PRO scores and survival measures, a large heter-
ogeneity of statistical methodologies was observed for other types of PRO analysis.
In most studies, the method was appropriate from a statistical perspective but not
adapted to the specific nature of PRO data, including under-use of clinically mean-
ingful interpretation of statistical results and absence of specific PRO approaches
such as cumulative distribution curves.
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USING A WEIBULL PARAMETRIC MODEL FOR FAILURE-TIME DATA TO ASSESS
PROGRESSION-FREE SURVIVAL AS A SURROGATE ENDPOINT FOR OVERALL
SURVIVAL IN A TRIAL OF PATIENTS WITH METASTATIC RENAL CELL
CARCINOMA
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OBJECTIVES: Among surrogate endpoints for overall survival (OS) in oncology tri-
als, progression-free survival (PFS) is increasingly taking the lead. Although there
have been some empirical investigations on inter-dependence of OS and PFS in
different tumor types, new ways to model and interpret this inter-dependence are
scarce, and only limited evidence is available for metastatic renal cell carcinoma
(mRCC). METHODS: We assessed the relationship between PFS (primary endpoint)
and OS in 750 patients with treatment-naïve mRCC randomized 1:1 to receive
sunitinib (SU) or interferon-alfa (IFN) in a pivotal phase III study, pooling data for all
available patients across treatment arms. A Weibull parametric model for failure-
time data was applied to the dataset. The difference between OS and PFS was used
as the outcome to remove inherent dependencies between PFS and OS. By exclud-
ing PFS time from OS time we obtain a distinct measure of survival beyond PFS:
post-progression survival (PPS). RESULTS: The model demonstrated that longer
PFS was significantly predictive of longer PPS (P0.001). Estimated median PPS time
was linked to a particular PFS time. For example, for PFS of 20 weeks, the median
PPS was 43.9 weeks (95% confidence interval [CI]: 40.1, 48.1); for PFS of 60 weeks, the
median PPS was 57.9 weeks (95% CI: 50.3, 66.7). A non-parametric Kaplan-Meier
approach supported these results. CONCLUSIONS: For patients with mRCC ran-
domized to either sunitinib or IFN, a distinct and quantifiable relationship was
found between PFS and PPS. This suggests that PFS can be used as a surrogate
measure for OS in mRCC, although more research is needed to generalize this
finding beyond this particular study. This novel statistical approach using the
Weibull parametric model can enrich the interpretation and understanding of that
relationship, with potential implications for clinical trial design.
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OBJECTIVES: Within the context of cost-effectiveness evaluations of cancer drug-
based therapies, the current project aims to describe trends over time in cost-
effectiveness literature, and investigate any potential ‘relationship’ between the
pharmaceutical industry involvement in literature and study outcomes.
METHODS: This study involves reviewing all eligible cancer cost-effectiveness
studies that were published during the five subsequent time blocks 1991-1994,
1995-1998, 1999-2002, 2003-2006, and 2007-2010. Descriptive and association sta-
tistical analyses were conducted as appropriate. RESULTS: Of 307 articles for in-
clusion in the study, 260 (85%) articles have been analyzed to date. While there is a
general increase in the publishing journals, the discipline of these has significantly
shifted from being mainly “medicine” and/or “hematology/oncology” to being
“healthcare science and services”, especially during the last time block. Also, ret-
rospective data is increasingly the major type of data utilized in the studied liter-
ature, with lack of meta-analysis data. There has been a significant increase in the
external funding of studies as well, both industry and nonprofit. Similar trend was
observed with the involvement of paid industry consultation. Surprisingly how-
ever, this is associated with an increase in paid consultations with no sponsorships
declared. This was also associated with general increasing absence of conflict of
interest declaration. Importantly, there has been a significant association between
industry funding and reported outcomes of sponsored-drug studies. This did not
exist when other type of funding was also involved in the sponsorship.
CONCLUSIONS:This is the first analysis of cost-effectiveness literature, whereby, it
demonstrated a clear evolvement over the past 20 years in terms of size, study
design and characteristics as well as funding. It seems that the absence of a dec-
laration of potential conflict of interest is inappropriately not decreasing in jour-
nals, in addition to that financial sponsorship by pharmaceutical industries is as-
sociated with favorable result to the sponsor.
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ASSOCIATION BETWEEN HYPOGLYCEMIA AND MEDICATION POSSESSION
RATIO AMONG VETERANS WITH TYPE 2 DIABETES MELLITUS (T2DM)
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OBJECTIVES: This retrospective cohort study aimed to examine the association
between hypoglycemia and medication adherence among veterans with type 2
diabetes mellitus (T2DM) in the United States. METHODS: Electronic medical and
pharmacy records were obtained for patients with at least 2 records of T2DM diag-
nosis (ICD-9-CM codes: 250.xx except for 250.x1 and 250.x3) from the Veterans
Integrated Service Network (VISN) 16 data warehouse from January 1, 2004 to Sep-
tember 1, 2010. The VISN 16 serves veterans in Arkansas, Louisiana, Mississippi,
Oklahoma, and parts of Alabama, Florida, Missouri, and Texas. The first dispense
date of a new antihyperglycemic agent (index drug) was defined as the index date.
The hypoglycemia and control cohorts were identified by the occurrence of hypo-
glycemia (ICD-9-CM codes: 250.8, 251.0, 251.1 and 251.2) during the index-treat-
ment period and no hypoglycemia during one-year post-index period, respectively.
Selected patients had no records of hypoglycemia, cardio-vascular disease, or mi-
cro-vascular complications during the one-year pre-index period. Selection bias
across cohorts was reduced using propensity score matching. The medication pos-
session ratio (MPR) and proportion of MPR80% of the index drug and overall
anti-hyperglycemic medications were used as indicators for medication adher-
ence. Generalized linear model and logistic regression model were used to compare
MPR and proportion of MPR80% between the two groups, respectively.
RESULTS: The 761 patients in the hypoglycemia group were matched with 761
patients from the control group of 43,500 patients. As to the index drug, MPR was
slightly higher in the hypoglycemia group (0.66 vs. 0.63; p0.009), but proportion of
MPR80% did not significantly differ between the groups (hypoglycemia: 38.44%
versus control: 36.06%; p0.3387), controlling for the covariates. Also no differ-
ences in MPR and proportion of MPR80% to overall antihyperglycemics were
found between the groups. CONCLUSIONS: It appears that there is little impact of
hypoglycemic event during treatment on the MPR statistics in this population.
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OBJECTIVES: In a prospective population-based study covering a German region
with 200.000 inhabitants, the incidence of severe hypoglycaemia (SH) and clinical
characteristics of the corresponding patients were longitudinally compared over
two four-year periods between 1997-2000 versus 2007-2010. METHODS: Blood glu-
cose testing was systematically performed in every emergency patient irrespective
of the presenting condition, either already prehospitally at the scene of the emer-
gency or immediately after the arrival at the emergency department, respectively.
SH was defined as a symptomatic event requiring treatment with intravenous
glucose and was confirmed by a blood glucose measurement of 50 mg/dl.
RESULTS: Warranting identical methodological conditions, our study revealed a
drastic increase of 87.5% in the frequency of SH (495 events in 2007-2010 versus 264
events in 1997-2000). There was no change in the distribution of SH within the
different types of diabetes. The incidence of SH between 1997-2000 versus 2007-
2010 increased considerably from 11.5 to 22.7 in patients withT1DM and from 18.5
to 32.5 in those with T2DM. We observed a clear shift towards intensification of
antihyperglycemic therapy as indicated by lower HbA1c values in increasingly
multimorbid subjects. Especially hypoglycemic subjects with T2DM were charac-
terized by a geriatric and multimorbid state (mean age 75 years) receiving addi-
tional comedication of 3.3 (1997–2000) versus 7.7 drugs (2007–2010) and suffering
from 3.6 versus 4.4 concomitant diseases with an increase in renal insufficiency
from 54% to 76% (respective p-values 0.001). CONCLUSIONS: The nationwide
growing incidence of diabetes might have substantially contributed to the consid-
erable increase of SH between 2007-2010. Furthermore, the increase of SH corre-
lated with the shift towards more stringent goals for metabolic control by official
German guidelines (currently HbA1c6.5%) and the implementation of Disease
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